UNLABELLED: What is already known about this subject. Gemcitabine is an anticancer drug which is metabolized to a number of metabolites, administered using different dosing regimens and increasingly used in combination with oxaliplatin. the impact of dosing strategies and combination therapy on the pharmacokinetics of gemcitabine and its main metabolite is not clearly understood. what this study adds. this study has characterized the pharmacokinetics of gemcitabine and its main metabolite in people with cancer, including the variability between patients and on different occasions. gemcitabine metabolite (but not gemcitabine) pharmacokinetics were significantly affected by co-administration with oxaliplatin and were dependent on the order of administration. the clinical implications of this observation remain to be established. AIMS: To characterize the population pharmacokinetics of gemcitabine and its metabolite (dfdu) in patients with cancer and identify factors that are influential in gemcitabine dose regimen design. METHODS: Gemcitabine and dfdu plasma concentration-time and clinical data from 94 patients with cancer and nonlinear mixed effect modelling were used to characterize gemcitabine and metabolite pharmacokinetic variability and identify influential covariates. RESULTS: Gemcitabine and dFdU pharmacokinetics were described by a two-compartment model with first-order elimination. The population mean (and between-subject variability, CV%) for clearance and volume of distribution of the central compartment (V(C)) for gemcitabine were 2.7 l min(-1) (31%) and 15 l (39%), respectively, and 0.04 l min(-1) (35%) and 46 l (15%), respectively, for dFdU. Oxaliplatin co-administration significantly decreased dFdU V(C) by 35% when gemcitabine was administered first and by 46% when oxaliplatin was administered first compared with patients who received gemcitabine alone. CONCLUSIONS: Co-administration of gemcitabine with oxaliplatin significantly affected the pharmacokinetics of dFdU. The clinical significance of this observation in the context of gemcitabine safety and efficacy is worthy of further investigation.
UNLABELLED: What is already known about this subject. Gemcitabine is an anticancer drug which is metabolized to a number of metabolites, administered using different dosing regimens and increasingly used in combination with oxaliplatin. the impact of dosing strategies and combination therapy on the pharmacokinetics of gemcitabine and its main metabolite is not clearly understood. what this study adds. this study has characterized the pharmacokinetics of gemcitabine and its main metabolite in people with cancer, including the variability between patients and on different occasions. gemcitabine metabolite (but not gemcitabine) pharmacokinetics were significantly affected by co-administration with oxaliplatin and were dependent on the order of administration. the clinical implications of this observation remain to be established. AIMS: To characterize the population pharmacokinetics of gemcitabine and its metabolite (dfdu) in patients with cancer and identify factors that are influential in gemcitabine dose regimen design. METHODS:Gemcitabine and dfdu plasma concentration-time and clinical data from 94 patients with cancer and nonlinear mixed effect modelling were used to characterize gemcitabine and metabolite pharmacokinetic variability and identify influential covariates. RESULTS:Gemcitabine and dFdU pharmacokinetics were described by a two-compartment model with first-order elimination. The population mean (and between-subject variability, CV%) for clearance and volume of distribution of the central compartment (V(C)) for gemcitabine were 2.7 l min(-1) (31%) and 15 l (39%), respectively, and 0.04 l min(-1) (35%) and 46 l (15%), respectively, for dFdU. Oxaliplatin co-administration significantly decreased dFdU V(C) by 35% when gemcitabine was administered first and by 46% when oxaliplatin was administered first compared with patients who received gemcitabine alone. CONCLUSIONS: Co-administration of gemcitabine with oxaliplatin significantly affected the pharmacokinetics of dFdU. The clinical significance of this observation in the context of gemcitabine safety and efficacy is worthy of further investigation.
Authors: A P Venook; M J Egorin; G L Rosner; D Hollis; S Mani; M Hawkins; J Byrd; R Hohl; D Budman; N J Meropol; M J Ratain Journal: J Clin Oncol Date: 2000-07 Impact factor: 44.544
Authors: Xuemin Jiang; Kenneth M Williams; Winston S Liauw; Alaina J Ammit; Basil D Roufogalis; Colin C Duke; Richard O Day; Andrew J McLachlan Journal: Br J Clin Pharmacol Date: 2004-05 Impact factor: 4.335
Authors: Stacy S Shord; Stephanie R Faucette; Heidi H Gillenwater; Scott L Pescatore; Roy L Hawke; Mark A Socinski; Celeste Lindley Journal: Cancer Chemother Pharmacol Date: 2003-03-13 Impact factor: 3.333
Authors: Suzette Delaloge; Antonio Llombart; Mario Di Palma; Jean-Marc Tourani; Francois Turpin; Lan Ni; S T Forgue; Thierry Le Chevalier Journal: Am J Clin Oncol Date: 2004-06 Impact factor: 2.339
Authors: S Faivre; T Le Chevalier; C Monnerat; F Lokiec; S Novello; J Taieb; P Pautier; C Lhommé; P Ruffié; L Kayitalire; J-P Armand; E Raymond Journal: Ann Oncol Date: 2002-09 Impact factor: 32.976
Authors: René J Boosman; Marie-Rose B S Crombag; Nielka P van Erp; Jos H Beijnen; Neeltje Steeghs; Alwin D R Huitema Journal: Cancer Chemother Pharmacol Date: 2022-04-15 Impact factor: 3.288
Authors: Ruth Plummer; Ayman Madi; Melinda Jeffels; Heike Richly; Bahar Nokay; Stephen Rubin; Howard A Ball; Steve Weller; Jeffrey Botbyl; Diana M Gibson; Max E Scheulen Journal: Cancer Chemother Pharmacol Date: 2012-10-11 Impact factor: 3.333
Authors: A Khatri; B W Williams; J Fisher; R C Brundage; V J Gurvich; L G Lis; K M Skubitz; A Z Dudek; E W Greeno; R A Kratzke; J K Lamba; M N Kirstein Journal: Br J Cancer Date: 2013-12-03 Impact factor: 7.640
Authors: Bart Kramer; Luuk de Haan; Marjolein Vermeer; Thomas Olivier; Thomas Hankemeier; Paul Vulto; Jos Joore; Henriëtte L Lanz Journal: Int J Mol Sci Date: 2019-09-19 Impact factor: 5.923